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INTRODUCTION:
Sjögren’s syndrome (SS) is a chronic autoimmune disorder affecting approximately 0.1–0.4% of the
general population with a female-to-male ratio of 9:1 usually diagnosed in the fourth and fifth decades of
life [1]. Clinically, SS is typified by ocular and oral dryness developed as a consequence of the
autoimmune process. It may occur either alone, as primary (p)SS, or secondary to other autoimmune
disease, often rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or systemic sclerosis,
secondary (s)SS. There is an increased risk of developing non-Hodgkin’s B cell lymphoma [1]. Altered B
cell subpopulations have also been correlated with disease activity [2]. B cell activating factor (BAFF)
and its receptor (BAFF-R) play an important role in activating a range of cell types. It is likely that their
activation could be affected by sphingolipid/cholesterol enriched membrane microdomains lipid rafts [3-4].
T cells were initially identified as the predominant cells within the salivary gland infiltrates and have
been shown to be involved in the generation and perpetuation of inflammatory infiltrates in salivary
glands in SS [5-6].
Aims
1.) Identify the peripheral B and T cell abnormalities in patients with pSS compared to SLE and
SS/SLE patients.
2.) Correlate immune phenotype with clinical features and serological abnormalities.
3.) Investigate lipid rafts expression in different B cell populations and molecular mechanisms
underlying B cell hyperactivity in patients with SS.
Table 1: Study subjects demographic detail and clinical characteristics.
CB19+ B cells, CD4+/CD8+ T cells and T follicular cells subpopulation
representative plots from peripheral blood mononuclear cells (PBMCs).
METHODS:
CD19+ B cell
subpopulations Surface marker
CD4+ or CD8+T 
cell
subpopulations Surface marker
CXCR5+
T follicular cell
subpopulations
Surface 
marker
Total B cells CD19+
Total CD4+ or 
CD8+ CD4+ or  CD8+ Total Tfh CD3/+CD4+CXCR5+
Transitional CD24+CD38+ T responder CD25-CD127+ T follicular helper CD127+CD25-
Mature CD24hiCD38int T activator CD25+CD127+ T follicular regulatory CD127+CD25+
Memory CD24hi CD38- T regulator CD25+CD127- Total activated Tfregs CXCR5+ Tfreg+ PD-1+ICOS+ 
Plasmablast CD24-CD38+ Unknown CD25-CD127- Total Activated Tfh CXCR5+Tfh+ICOS+PD-1+
Bm1 - Naïve IgD+CD38- EMRA CD27-CD45RA+ Tfh 1 CCR6-CXCR3+
Bm2 - Naïve IgD+CD38+ Naïve CD27+CD454A+ Tfh2 CCR6-CXCR3-
Bm2 – Bm2’ 
Transitional IgD+CD38++ Central memory CD27+CD45RA+ Tfh17
CCR6+CXCR3-
Bm3 – Bm4’  
Plasmablast IgD-CD38++ Effector memory CD27-CD45RA- Activated Tfh 1
CCR6-CXCR3+ICOS+PD-1+ 
early Bm5 IgD-CD38+ Activated Tfh2 CCR6-CXCR3- ICOS+PD-1+ 
late Bm5 IgD-CD38- Tfh17 CCR6+CXCR3- ICOS+PD-1+
Switched memory IgD-CD27+ 
Unswitched memory IgD+CD27+ 
Naïve IgD+CD27-
Double negative IgD-CD27-
Table 2: B cell, T cell, lipid raft, BAFF-R and T follicular cell
subpopulations and expression markers.
RESULTS:
Distinct  distribution of B cell, T cell and T follicular cell subpopulations in pSS, 
SLE and SS/SLE compared to healthy donors.
Heatmaps comparing expression of T and B cell populations in healthy donors compared to patients with SS, SLE and 
SS/SLE. Lipid rafts were also significantly elevated in B cells from patients wit SS and SLE but not SLE/SS.
Correlation between clinical parameters and  Bm1-Bm5 subpopulations in patients 
with  pSS, SLE and  SS/SLE.
A significant positive correlation was seen between B cell lipid raft expression and disease activity in patients with SS.
Significant positive correlation between B cell BAFF-R and lipid raft expression in 
healthy donors but not patients with SS, SLE and SS/SLE. 
Altered association of BAFF-R and IgD with lipid rafts in patients with pSS, SLE
and SS/SLE compared to healthy donors.
DISCUSSION/CONCLUSIONS:
 SS/SLE have the most striking B cell phenotype abnormalities than patients with pSS or SLE (increased
Bm2 cells and decreased early and late Bm5 cells).
 SS/SLE patients also shared B cell phenotype abnormalities with pSS (decreased early Bm5 cells) and
SLE (increased Bm2’ cells).
 These abnormalities suggest disturbance of B cell trafficking in the patient groups, and a possible bias
towards plasma cell differentiation (as they all had low memory B cells)
 Significant correlations between lipid rafts expression and disease activity in patients with pSS, which
suggest abnormal B cell signalling (never explored before).
 Altered colocalisation of BAFF-R and lipid rafts in patients with pSS, SLE and SS/SLE compared to
healthy donors.
 This is the first comprehensive immunophenotype analysis performed patients with pSS and SS/SLE,
which identified that the SS/SLE patient group is immunologically distinct from pSS and SLE patients.
 Lipid raft abnormalities could be relevant for the variability of patients’ response to biologic treatments in
SLE compared to pSS, as B cell targeted monoclonal antibodies are internalised within the lipid rafts.
Representative flow cytometry dotplots showing CB19+ B cells, CD4+/CD8+ T cells and T follicular cell 
subpopulations. 
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